Professional Summary »
Specializing In »
Practice Locations »
Patient Ratings »
Referring Physicians »
Biography
Dr. Rezvani is an Associate Professor of Medicine in the Division of Blood & Marrow Transplantation and Cell Therapy. He serves as the medical director of the inpatient BMT/cell therapy units at Stanford University and as Associate Clinical Chief of the Division. As a clinician, he cares for people undergoing allogeneic and autologous hematopoietic cell transplantation and other forms of cellular therapy. His research interests include optimizing the use of alternative donors for people who lack traditional fully-matched donors; the prevention and treatment of graft-vs.-host disease; the role of the microbiome in hematopoietic cell transplantation; and quality-of-care and systems improvement. He also teaches and serves as a research mentor for trainees in the Division of Blood & Marrow Transplant at Stanford.
View Full Biography »
Professional Summary
Professional Education
- Board Certification: American Board of Internal Medicine, Medical Oncology (2021)
- Fellowship, Fred Hutchinson Cancer Research Center/University of Washington, Medical Oncology (2008)
- Residency, Duke University Medical Center, Internal Medicine (2004)
- M.D., Temple University, Medicine (2001)
- B.A., Stanford University, Slavic Languages and Literature (1997)
Honors & Awards
- Member, Alpha Omega Alpha medical honor society (2001)
Administrative Appointments
- Associate Clinical Chief, Stanford University, Division of Blood & Marrow Transplantation (2020 - Present)
- Cord Blood and Unrelated-Donor Director, Stanford University, Division of Blood & Marrow Transplantation (2018 - Present)
- Inpatient Medical Director, Blood & Marrow Transplant Unit, Stanford University (2017 - Present)
- Quality & Safety Director, Division of Blood & Marrow Transplantation (2021 - Present)
Publications
-
Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma
Rezvani, A. R., Storer, B., Maris, M., Sorror, M. L., Agura, E., Maziarz, R. T., … Maloney, D. G. (2008). Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 26(2), 211–17. -
Outcomes of allogeneic hematopoietic cell transplantation (HCT) after non-myeloablative conditioning in relapsed diffuse large B-cell lymphoma (DLBCL)
Rezvani, A. R., Norasetthada, L., Gooley, T., Sorror, M., Forman, S. J., Agura, E., … Maloney, D. G. (2007). Outcomes of allogeneic hematopoietic cell transplantation (HCT) after non-myeloablative conditioning in relapsed diffuse large B-cell lymphoma (DLBCL). BLOOD, 110(11), 892A–892A. -
Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience
Rezvani, A. R., Norasetthada, L., Gooley, T., Sorror, M., Bouvier, M. E., Sahebi, F., … Maloney, D. G. (2008). Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. BRITISH JOURNAL OF HAEMATOLOGY, 143(3), 395–403. -
Using allogeneic stem cell/T-cell grafts to cure hematologic malignancies
Rezvani, A. R., & Storb, R. (2008). Using allogeneic stem cell/T-cell grafts to cure hematologic malignancies. EXPERT OPINION ON BIOLOGICAL THERAPY, 8(2), 161–179. -
Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation
Rezvani, A. R., & Storb, R. F. (2008). Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation. JOURNAL OF AUTOIMMUNITY, 30(3), 172–179. -
Treatment Change as a Predictor of Outcome among Patients with Classic Chronic Graft-versus-Host Disease
Flowers, M. E. D., Storer, B., Carpenter, P., Rezvoni, A. R., Vigorito, A. C., Campregher, P. V., … Martin, P. J. (2008). Treatment Change as a Predictor of Outcome among Patients with Classic Chronic Graft-versus-Host Disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 14(12), 1380–1384. -
Allogeneic hematopoietic cell transplantation: the state of the art
Gyurkocza, B., Rezvani, A., & Storb, R. F. (2010). Allogeneic hematopoietic cell transplantation: the state of the art. EXPERT REVIEW OF HEMATOLOGY, 3(3), 285–299. -
Rituximab resistance
Rezvani, A. R., & Maloney, D. G. (2011). Rituximab resistance. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 24(2), 203–216. -
Accurate Targeting of Daily Intravenous Busulfan with 8-Hour Blood Sampling in Hospitalized Adult Hematopoietic Cell Transplant Recipients
Yeh, R. F., Pawlikowski, M. A., Blough, D. K., McDonald, G. B., O'Donnell, P. V., Rezvani, A., … McCune, J. S. (2012). Accurate Targeting of Daily Intravenous Busulfan with 8-Hour Blood Sampling in Hospitalized Adult Hematopoietic Cell Transplant Recipients. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 18(2), 265–272. -
Decreased Serum Albumin as a Biomarker for Severe Acute Graft-versus-Host Disease after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation
Rezvani, A. R., Storer, B. E., Storb, R. F., Mielcarek, M., Maloney, D. G., Sandmaier, B. M., … McDonald, G. B. (2011). Decreased Serum Albumin as a Biomarker for Severe Acute Graft-versus-Host Disease after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(11), 1594–1601. -
The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation
Scott, B. L., Gooley, T. A., Sorror, M. L., Rezvani, A. R., Linenberger, M. L., Grim, J., … Deeg, H. J. (2012). The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. BLOOD, 119(11), 2657–2664. -
Prevention of graft-vs.-host disease
Rezvani, A. R., & Storb, R. F. (2012). Prevention of graft-vs.-host disease. EXPERT OPINION ON PHARMACOTHERAPY, 13(12), 1737–1750. -
Cyclophosphamide followed by Intravenous Targeted Busulfan for Allogeneic Hematopoietic Cell Transplantation: Pharmacokinetics and Clinical Outcomes
Rezvani, A. R., McCune, J. S., Storer, B. E., Batchelder, A., Kida, A., Deeg, H. J., & McDonald, G. B. (2013). Cyclophosphamide followed by Intravenous Targeted Busulfan for Allogeneic Hematopoietic Cell Transplantation: Pharmacokinetics and Clinical Outcomes. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(7), 1033–1039. -
Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target.
Sato, M., Storb, R., Loretz, C., Stone, D., Mielcarek, M., Sale, G. E., … Graves, S. S. (2013). Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target. Transplantation, 96(1), 34–41. -
Allogeneic hematopoietic cell transplantation for indolent non-Hodgkin lymphoma: indications and outcomes
Rezvani, A. R., & Sandmaier, B. M. (2013). Allogeneic hematopoietic cell transplantation for indolent non-Hodgkin lymphoma: indications and outcomes. CURRENT OPINION IN HEMATOLOGY, 20(6), 509–514. -
Impact of donor age on outcome after allogeneic hematopoietic cell transplantation.
Rezvani, A. R., Storer, B. E., Guthrie, K. A., Schoch, H. G., Maloney, D. G., Sandmaier, B. M., & Storb, R. (2015). Impact of donor age on outcome after allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation , 21(1), 105–12. -
Long-term outcomes of patients with persistent indolent b cell malignancies undergoing nonmyeloablative allogeneic transplantation.
Cassaday, R. D., Storer, B. E., Sorror, M. L., Sandmaier, B. M., Guthrie, K. A., Maloney, D. G., … Gopal, A. K. (2015). Long-term outcomes of patients with persistent indolent b cell malignancies undergoing nonmyeloablative allogeneic transplantation. Biology of Blood and Marrow Transplantation , 21(2), 281–87. -
Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
Vaughn, J. E., Sorror, M. L., Storer, B. E., Chauncey, T. R., Pulsipher, M. A., Maziarz, R. T., … Maloney, D. G. (2015). Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Cancer, 121(20), 3709–16. -
Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning
Rezvani, A. R., Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H. E., Shizuru, J. A., … Lowsky, R. (2015). Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning. BONE MARROW TRANSPLANTATION, 50(10), 1286–92. -
Microbiota Manipulation With Prebiotics and Probiotics in Patients Undergoing Stem Cell Transplantation
Andermann, T. M., Rezvani, A., & Bhatt, A. S. (2016). Microbiota Manipulation With Prebiotics and Probiotics in Patients Undergoing Stem Cell Transplantation. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 11(1), 19–28. -
Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors
Kanate, A. S., Mussetti, A., Kharfan-Dabaja, M. A., Ahn, K. W., DiGilio, A., Beitinjaneh, A., … Hamadani, M. (2016). Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. BLOOD, 127(7), 938–47. -
A new standard for HIV-associated lymphoma.
Rezvani, A. R. (2016). A new standard for HIV-associated lymphoma. Blood, 128(8), 1026–27. -
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
Ryan, C. E., Sahaf, B., Logan, A. C., O'Brien, S., Byrd, J. C., Hillmen, P., … Miklos, D. B. (2016). Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood. -
Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission.
Weisdorf, D. J., Millard, H. R., Horowitz, M. M., Hyare, P. S., Champlin, R., Ho, V., … Eapen, M. (2017). Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission. Cancer. -
Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma.
Epperla, N., Ahn, K. W., Ahmed, S., Jagasia, M., DiGilio, A., Devine, S. M., … Hamadani, M. (2017). Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. Journal of Hematology & Oncology, 10(1), 117. -
HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.
Spinner, M. A., Fernández-Viña, M., Creary, L. E., Quinn, O., Elder, L., Arai, S., … Rezvani, A. R. (2017). HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. Blood Advances, 1(17), 1347–57. -
Long-Term Outcomes of AML Patients Using Total Lymphoid Irradiation with Anti-Thymocyte Globulin
Nakasone, H., Miklos, D. B., Meyer, E., Rezvani, A., Muffly, L., Weng, W.-K., … Lowsky, R. (2016). Long-Term Outcomes of AML Patients Using Total Lymphoid Irradiation with Anti-Thymocyte Globulin. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 22(3), S204–S205. -
Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms
Narayan, R., Benjamin, J., Laport, G., Tian, L., Tate, K., Elder, L., … Meyer, E. (2015). Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms. BLOOD, 126(23). -
Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation
Muffly, L., Sheehan, K., Armstrong, R., Jensen, K., Tate, K., Rezvani, A. R., … Lowsky, R. (2018). Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation. BLOOD ADVANCES, 2(6), 681–90. -
Viral Isolates in the Cerebrospinal Fluid of Hematopoietic Stem Cell Transplant Recipients, 2007-2015
Andermann, T., Asiimwe, E., Buckley, M., Tkachenko, E., Greene, C., Rezvani, A., & Bhatt, A. S. (2018). Viral Isolates in the Cerebrospinal Fluid of Hematopoietic Stem Cell Transplant Recipients, 2007-2015. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 24(3), S378–S379. -
Phase I/II Trial for Patients with Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT with a T Cell Depleted Graft with Infusion of Conventional T Cells and Regulatory T Cells
Meyer, E., Laport, G. G., Tantsura, I., Tang, S. W., Sahaf, B., Rangarajan, K., … Negrin, R. S. (2018). Phase I/II Trial for Patients with Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT with a T Cell Depleted Graft with Infusion of Conventional T Cells and Regulatory T Cells. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 24(3), S145. -
Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis
Chu, M. P., Brody, J., Kohrt, H. E., Frank, M. J., Khodadoust, M., Reddy, S., … Levy, R. (2015). Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis. BLOOD. AMER SOC HEMATOLOGY. -
Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis
Shah, N. N., Ahn, K. W., Litovich, C., Fenske, T. S., Ahmed, S., Battiwalla, M., … Hamadani, M. (2018). Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. BLOOD ADVANCES, 2(8), 933–40. -
Acute Graft-versus-Host Disease
Rezvani, A. R. (2018). Acute Graft-versus-Host Disease. NEW ENGLAND JOURNAL OF MEDICINE, 378(6), 585–86. -
Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation
Veeraputhiran, M., Yang, L., Sundaram, V., Arai, S., Lowsky, R., Miklos, D., … Johnston, L. (2017). Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 23(10), 1744–48. -
Immune Characterization of Ibrutinib Therapy Following Allohct That Provides GVL Benefit without Gvhd
Sahaf, B., Ryan, C. E., Rezvani, A., Nakasone, H., Otani, J., Coutre, S., … Miklos, D. B. (2016). Immune Characterization of Ibrutinib Therapy Following Allohct That Provides GVL Benefit without Gvhd. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 22(3), S412. -
Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis
Casulo, C., Friedberg, J. W., Ahn, K. W., Flowers, C., DiGilio, A., Smith, S. M., … Hamadani, M. (2018). Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 24(6), 1163–71. -
Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors
Spinner, M. A., Vina, M. F., Elder, L., Arai, S., Johnston, L., Meyer, E., … Rezvani, A. R. (2016). Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors. BLOOD, 128(22). -
Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation
Muffly, L. S., Sheehan, K., Armstrong, R., Tate, K., Tudisco, C., Rezvani, A. R., … Lowsky, R. (2016). Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation. BLOOD, 128(22). -
Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis.
Epperla, N., Ahn, K. W., Litovich, C., Ahmed, S., Battiwalla, M., Cohen, J. B., … Hamadani, M. (2019). Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. Journal of Hematology & Oncology, 12(1), 6. -
Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Elder, L. V., Arai, S., … Lowsky, R. (2018). Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort. BLOOD, 132. -
Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma
Spiegel, J. Y., Sahaf, B., Hossain, N., Frank, M. J., Claire, G., Abramian, M., … Miklos, D. B. (2018). Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma. BLOOD, 132. -
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States
Muffly, L., Pasquini, M. C., Martens, M., Brazauskas, R., Zhu, X., Adekola, K., … Artz, A. (2017). Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. BLOOD, 130(9), 1156–64. -
Molecular Remission One Year Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia Predicts Relapse-Free and Overall Survival: A Multi-Institutional Landmark Analysis
Logan, A. C., Herrera, A. F., Ryan, C. E., Rezvani, A. R., Kong, K. A., Faham, M., … Miklos, D. B. (2015). Molecular Remission One Year Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia Predicts Relapse-Free and Overall Survival: A Multi-Institutional Landmark Analysis. BLOOD, 126(23). -
Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation
Ryan, C. E., Logan, A. C., Rezvani, A., Kamdar, M., Nakasone, H., Sahaf, B., … Miklos, D. B. (2014). Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation. BLOOD, 124(21). -
Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation
Ryan, C. E., Logan, A. C., Rezvani, A., Kamdar, M., Nakasone, H., Sahaf, B., … Miklos, D. B. (2015). Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 21(2), S307–S308. -
Long-Term Outcomes of Patients with Advanced Mantle Cell Lymphoma Treated with Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning
Vaughn, J., Sorror, M. L., Chauncey, T., Pulsipher, M. A., Maziarz, R. T., Maris, M. B., … Maloney, D. G. (2015). Long-Term Outcomes of Patients with Advanced Mantle Cell Lymphoma Treated with Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 21(2), S88–S89. -
Outcomes Following Relapse of Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) After Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors.
Sorror, M. L., Storer, B., Sandmaier, B. M., Franke, G. N., Laport, G. G., Chauncey, T., … Maloney, D. G. (2010). Outcomes Following Relapse of Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) After Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors. BLOOD, 116(21), 553. -
Microbiota Manipulation With Prebiotics and Probiotics in Patients Undergoing Stem Cell Transplantation.
Andermann, T. M., Rezvani, A., & Bhatt, A. S. (2016). Microbiota Manipulation With Prebiotics and Probiotics in Patients Undergoing Stem Cell Transplantation. Current Hematologic Malignancy Reports. -
Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients
Meyer, E. H., Laport, G., Xie, B. J., MacDonald, K., Heydari, K., Sahaf, B., … Negrin, R. S. (2019). Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. JCI INSIGHT, 4(10). -
Validation of the hematopoietic cell transplantation-specific comorbidity index in non-myeloablative allogeneic stem cell transplantation.
Veeraputhiran, M., Arai, S., Lowsky, R., Miklos, D. B., Meyer, E., Muffly, L. S., … Johnston, L. J. (2016). Validation of the hematopoietic cell transplantation-specific comorbidity index in non-myeloablative allogeneic stem cell transplantation. JOURNAL OF CLINICAL ONCOLOGY, 34(15). -
Incidence of Active Tuberculosis Following Hematopoietic Cell Transplantation: A Small but Real Threat.
Aronson, J. R., Rezvani, A. R., & Subramanian, A. (2019). Incidence of Active Tuberculosis Following Hematopoietic Cell Transplantation: A Small but Real Threat. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. -
Long-term outcomes of high-dose melphalan and carmustine followed by autologous hematopoietic cell transplantation for multiple myeloma.
Neppalli, A. K., Shizuru, J., Johnston, L. J., Muffly, L. S., Weng, W.-K., Negrin, R., … Rezvani, A. R. (2016). Long-term outcomes of high-dose melphalan and carmustine followed by autologous hematopoietic cell transplantation for multiple myeloma. JOURNAL OF CLINICAL ONCOLOGY, 34(15). -
Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Arai, S., Johnston, L. J., … Lowsky, R. (2019). Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. Blood Advances, 3(16), 2454–64. -
Costs and outcomes with once-daily versus every-six-hour intravenous busulfan in allogeneic hematopoietic cell transplantation.
Singhal, S., Kim, T., Jenkins, P., Bassett, B., Tierney, D. K., & Rezvani, A. R. (2019). Costs and outcomes with once-daily versus every-six-hour intravenous busulfan in allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. -
Missed diagnosis and misdiagnosis of infectious diseases in hematopoietic cell transplant recipients: an autopsy study.
Multani, A., Allard, L. S., Wangjam, T., Sica, R. A., Epstein, D. J., Rezvani, A. R., & Ho, D. Y. (2019). Missed diagnosis and misdiagnosis of infectious diseases in hematopoietic cell transplant recipients: an autopsy study. Blood Advances, 3(22), 3602–12. -
Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era
Muffly, L., Arai, S., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., … Cunanan, K. (2020). Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 26(3), S106. -
Prospective Randomized Study of Advance Directives in Allogeneic Hematopoietic Cell Transplant Recipients
Muffly, L., Ramirez, Y., Burnash, S., Bisetti, E., Rezvani, A., & Sundaram, V. (2020). Prospective Randomized Study of Advance Directives in Allogeneic Hematopoietic Cell Transplant Recipients. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 26(3), S199. -
Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases.
Kahn, J. M., Brazauskas, R., Tecca, H. R., Bo-Subait, S., Buchbinder, D., Battiwala, M., … Satwani, P. (2020). Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Blood Advances, 4(9), 2084–94. -
Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.
Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., … Levy, R. (2020). Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. The Journal of Experimental Medicine, 217(9). -
Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B-cell Malignancies.
Granot, N., Rezvani, A. R., Pender, B. S., Storer, B. E., Sandmaier, B. M., Storb, R., & Maloney, D. G. (2020). Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B-cell Malignancies. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. -
Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.
Lemieux, C., Muffly, L. S., Rezvani, A., Lowsky, R., Iberri, D. J., Craig, J. K., … Sidana, S. (2020). Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma. Bone Marrow Transplantation. -
Double unrelated umbilical cord blood versus HLA-haploidentical bone marrow transplantation (BMT CTN 1101).
Fuchs, E. J., O'Donnell, P. V., Eapen, M., Logan, B. R., Antin, J. H., Dawson, P., … Brunstein, C. G. (2020). Double unrelated umbilical cord blood versus HLA-haploidentical bone marrow transplantation (BMT CTN 1101). Blood. -
Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma.
Weng, W.-K. K., Arai, S., Rezvani, A., Johnston, L., Lowsky, R., Miklos, D., … Kim, Y. H. (2020). Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. Blood Advances, 4(18), 4474–82. -
Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents.
Lemieux, C., Johnston, L. J., Lowsky, R., Muffly, L. S., Craig, J. K., Shiraz, P., … Sidana, S. (2020). Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. -
Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents
Sica, R. A., Spinner, M. A., Tamaresis, J. S., Advani, R. H., Johnston, L. J., Lowsky, R., … Arai, S. (2019). Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents. BLOOD. AMER SOC HEMATOLOGY. -
Dose-Intense BCNU/Melphalan Regimen Followed By Autologous Hematopoietic Cell Transplantation (AHCT) Results in Prolonged PFS in Myeloma Patients
Gandhi, A., Rezvani, A., Lowsky, R., Johnston, L., Shizuru, J. A., Miklos, D. B., … Weng, W.-K. (2019). Dose-Intense BCNU/Melphalan Regimen Followed By Autologous Hematopoietic Cell Transplantation (AHCT) Results in Prolonged PFS in Myeloma Patients. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC. -
Daily Dosing of Busulfan in Allogeneic Hematopoietic Cell Transplantation Reduces Costs with Equivalent or Superior Outcomes
Singhal, S., Kim, T. Y., Tierney, D. K., & Rezvani, A. (2019). Daily Dosing of Busulfan in Allogeneic Hematopoietic Cell Transplantation Reduces Costs with Equivalent or Superior Outcomes. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC. -
No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Compared to Conventional CBT: Results of a Randomized Trial
Milano, F., Rezvani, A. R., Kurtzberg, J., Karanes, C., Gutman, J. A., Duncan, C., … Delaney, C. (2019). No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Compared to Conventional CBT: Results of a Randomized Trial. BLOOD. AMER SOC HEMATOLOGY. -
Results of Bmt Ctn Protocol 1101 a Multicenter Phase Iii Randomized Trial of Transplantation of Double Umbilical Cord Blood vs. Hla-haploidentical-related Bone Marrow
Brunstein, C., O'Donnell, P. V., Eapen, M., Logan, B., Antin, J. H., Dawson, P., … Fuchs, E. J. (2020). Results of Bmt Ctn Protocol 1101 a Multicenter Phase Iii Randomized Trial of Transplantation of Double Umbilical Cord Blood vs. Hla-haploidentical-related Bone Marrow. BONE MARROW TRANSPLANTATION. SPRINGERNATURE. -
Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial.
Fuchs, E. J., O'Donnell, P. V., Eapen, M., Logan, B., Antin, J. H., Dawson, P., … Brunstein, C. G. (2021). Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. Blood, 137(3), 420–428. -
CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.
Baird, J. H., Frank, M. J., Craig, J., Patel, S., Spiegel, J. Y., Sahaf, B., … Muffly, L. (2020). CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma. Blood. -
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., … Sidana, S. (2021). Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. BLOOD ADVANCES, 5(1), 143–55. -
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.
Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., … Sidana, S. (2021). Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. Blood Advances, 5(1), 143–155. -
Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma.
Lemieux, C., Muffly, L. S., Iberri, D. J., Rezvani, A., Lowsky, R., Frank, M. J., … Sidana, S. (2020). Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM).
Tam, E. L., Iberri, D. J., Liedtke, M., Muffly, L. S., Shiraz, P., Frank, M. J., … Sidana, S. (2020). Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
Liang, E. C., Muffly, L. S., Shiraz, P., Shizuru, J. A., Johnston, L., Arai, S., … Sidana, S. (2021). Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy. -
Guidelines for Adult Patient Selection and Conditioning Regimens in Cord Blood Transplant Recipients with Hematologic Malignancies and Aplastic Anemia.
Metheny, L., Politikos, I., Ballen, K. K., Rezvani, A. R., Milano, F., Barker, J. N., & Brunstein, C. G. (2021). Guidelines for Adult Patient Selection and Conditioning Regimens in Cord Blood Transplant Recipients with Hematologic Malignancies and Aplastic Anemia. Transplantation and Cellular Therapy, 27(4), 286–91. -
Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era.
Johnsrud, A., Ladha, A., Muffly, L., Shiraz, P., Goldstein, G., Osgood, V., … Sidana, S. (2021). Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era. Transplantation and Cellular Therapy. -
Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.
Scordo, M., Wang, T. P., Ahn, K. W., Chen, Y., Ahmed, S., Awan, F. T., … Sauter, C. S. (2021). Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. JAMA Oncology. -
Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma.
Lemieux, C., Muffly, L. S., Iberri, D. J., Craig, J. K., Johnston, L. J., Lowsky, R., … Sidana, S. (2021). Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma. Bone Marrow Transplantation. -
Omidubicel Versus Standard Myeloablative Umbilical Cord Blood Transplantation: Results of a Phase III Randomized Study.
Horwitz, M. E., Stiff, P. J., Cutler, C. S., Brunstein, C. G., Hanna, R., Maziarz, R. T., … Sanz, G. F. (2021). Omidubicel Versus Standard Myeloablative Umbilical Cord Blood Transplantation: Results of a Phase III Randomized Study. Blood. -
Inferior Clinical Outcomes in Recipients of Cryopreserved Grafts Following Reduced Intensity Allogeneic Hematopoietic Cell Transplantation: A Single Center Report
Bankova, A., Caveney, J., Ramos, T., Bogeholz, J., Heydari, K., Diaz, N., … Arai, S. (2021). Inferior Clinical Outcomes in Recipients of Cryopreserved Grafts Following Reduced Intensity Allogeneic Hematopoietic Cell Transplantation: A Single Center Report. BONE MARROW TRANSPLANTATION. SPRINGERNATURE. -
A fructo-oligosaccharide prebiotic is well-tolerated in adults undergoing allogeneic hematopoietic stem cell transplantation: a phase I dose-escalation trial.
Andermann, T. M., Fouladi, F., Tamburini, F. B., Sahaf, B., Tkachenko, E., Greene, C., … Bhatt, A. S. (2021). A fructo-oligosaccharide prebiotic is well-tolerated in adults undergoing allogeneic hematopoietic stem cell transplantation: a phase I dose-escalation trial. Transplantation and Cellular Therapy. -
Engraftment of double cord blood transplantation after non-myeloablative conditioning with escalated total body irradiation dosing to facilitate engraftment in immunocompetent patients.
Brunstein, C. G., DeFor, T. E., Fuchs, E. J., Karanes, C., McGuirk, J. P., Rezvani, A. R., … Weisdorf, D. J. (2021). Engraftment of double cord blood transplantation after non-myeloablative conditioning with escalated total body irradiation dosing to facilitate engraftment in immunocompetent patients. Transplantation and Cellular Therapy. -
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.
Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., … Miklos, D. B. (2021). CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine. -
Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.
Muffly, L., Sundaram, V., Chen, C., Yurkiewicz, I., Kuo, E., Burnash, S., … Miklos, D. B. (2021). Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia. Blood Advances, 5(16), 3147–3151. -
Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy.
Johnsrud, A. J., Craig, J., Baird, J. H., Spiegel, J. Y., Muffly, L., Zehnder, J. L., … Sidana, S. (2021). Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy. Blood Advances. -
Umbilical cord blood or HLA-haploidentical transplantation: Real world outcomes vs randomized trial outcomes.
O'Donnell, P. V., Brunstein, C. G., Fuchs, E. J., Zhang, M.-J. J., Allbee-Johnson, M., Antin, J. H., … Eapen, M. (2021). Umbilical cord blood or HLA-haploidentical transplantation: Real world outcomes vs randomized trial outcomes. Transplantation and Cellular Therapy. -
Phase 2 study of MGTA-145+plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma.
Sidana, S., Bankova, A., Hosoya, H., Muffly, L. S., Kumar, S., Johnston, L. J., … Miklos, D. B. (2021). Phase 2 study of MGTA-145+plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy
Johnsrud, A., Craig, J., Baird, J., Spiegel, J., Muffly, L., Zehnder, J., … Sidana, S. (2021). Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. BLOOD ADVANCES, 5(21), 4465–4475. -
Real-world Experience of Cryopreserved Allogeneic Hematopoietic Grafts in the COVID-19 Pandemic: A Single Center Report.
Bankova, A. K., Caveney, J., Yao, B., Ramos, T. L., Bogeholz, J., Heydari, K., … Arai, S. (1800). Real-world Experience of Cryopreserved Allogeneic Hematopoietic Grafts in the COVID-19 Pandemic: A Single Center Report. Transplantation and Cellular Therapy. -
Rare transmission of commensal and pathogenic bacteria in the gut microbiome of hospitalized adults.
Siranosian, B. A., Brooks, E. F., Andermann, T., Rezvani, A. R., Banaei, N., Tang, H., & Bhatt, A. S. (1800). Rare transmission of commensal and pathogenic bacteria in the gut microbiome of hospitalized adults. Nature Communications, 13(1), 586. -
Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant.
Savani, M., Ahn, K. W., Chen, Y., Ahmed, S., Cashen, A. F., Shadman, M., … Hamadani, M. (1800). Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant. British Journal of Haematology.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- A Study of Obinutuzumab for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation »
- Safety Study of Cord Blood Units for Stem Cell Transplants »
- Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies »
- CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma »
- Bone Marrow Grafting for Leukemia and Lymphoma »
- Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant »
- Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors »
- MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC »
- Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation »
- Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes »
- Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant »
- Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant »
- Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS »
- TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801) »
- Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) »
- A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1) »
Practice Locations
Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive Palo Alto, CA
Palo Alto, CA
Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive
900 Blake Wilbur Drive, 2nd Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Patient Reviews
(65 reviews)
I had a very pleasant visit I am totally pleased
He explained my procedure that I could understand and answered all the questions that I had. I could understand what he was saying. Very polite
Love him ♥ï¸
Dr. Rezvani in my opinion is an excellent physician in all aspects of his field.
Dr. Rezvani is an excellent doctor. As a patient he addresses all my concerns and explains concerns so I can easily understand.
I think he’s an excellent doctor, easy to talk to, good at involving the patient in decisions about their health. He’s very good about following up on any issues. I’ve been very pleased with him.
I’m so happy to Have him as my doctor. Is excellent!!
Thorough, considerate, and I'm glad he's my doc
I've been Dr. Rezvani's patient since January 2017. He has provided sound medical advice and information, but more importantly for a patient, shown patience and understanding towards the emotional/mental aspect of a patient's "journey," Not many physicians have this thoughtfulness.
I’m grateful that Dr. Rezvani is in charge of my health. Thanks to him and his team I am alive.
Dr. Rezvani is a fabulous doctor. He is kind, attentive and an excellent communicator...I've been very lucky to have him assigned to my care.
He’s a great doctor. He is also a good listener and he explains to you the details for the procedure, and he makes you feel comfortable.
Good experience.
Dr. Rezvani has the ability to appear that I was his only patient despite his busy schedule.
I was thankful for his honesty and explaining the process very helpful in making a decision.
While Dr. Rezvani was with me I felt like he was completely focused on my needs. I didn't feel rushed.
Dr. Rezvani is very knowledgeable and has a very good "bedside manner."
Dr. Rezvani was very professional, friendly and caring.
Very professional and respectful.
All excellent.
They have always attended to me with professionalism and kindness.
Dr. Rezvani showed amazing patience in answering all our questions.
Everything is perfect.
Very, very good. I love you all. 100% good. God bless you.
Dr. Rezvani is great!!!
We used a translator - However, all the people that we saw on my visit were very professional, empathetic. - Excellent services.
We couldn't be more pleased with Dr. Rezvani & his staff.
Dr. Rezvani is a great doctor. He is very knowledgeable, caring, and understanding. he has provided me the best treatments and hope. Thank you.
I've had very good experience with all care at Stanford Health.
Every visit with Dr. Rezvani and his staff has exceeded my expectations. I leave with encouragement, confidence and the answer to all my questions.
Wife care provider.
Very pleased.
Dr. Andrew Rezvani is great.
Wonderful experience from beginning to end. I got every question answered and I didn't feel rushed at all.
I am very happy with the personal service I received.
Dr. Rezvani had answers for my multitudes of questions. He was very patient and kind!
Dr. Rezvani was great and answered all the questions I had and I am looking forward to being under his care.
Dr. Rezvani very compassionate doctor - good listener, very knowledgeable. Very satisfied with visits and his availability.
Dr. Rezvani is knowledgeable, patient, and very thorough.
I wish all my doctors were like Dr. Rezvani. He always listens to me. Answers all my questions and concerns. he always takes his time.
Really like Dr. R.
Great!
Dr. Rezvani is wonderful. Always listens. Never makes me feel like we are keeping him from his work. Great doctor.
Very very confident in Dr. Rezvani -
Great doctor, very knowledgeable. Thank you very much.
Great doctor very happy with my experience!
Dr. Rezvani explained the transplant procedure in words all could understand and answered all questions. Very friendly and caring. Feel very lucky to have him.
My doctor all the time has been concerned about me, always listens to my symptoms or my concerns & always takes his time to explain my concerns or comments -
Dr. Rezvani did not rush through the visit and was very clear and patient answering my questions.
Very good experience, excellent representation (in detail) of illness!
Dr. Rezvani always gives me all the time & information I need - he's great!
I am very fortunate to have Dr. Rezvani as my BMT physician.
Dr. Rezvani is wonderful and caring doctor. Always clear on his explanations, very knowledgeable.
Dr. Rezvani took Dr. LaPorte's place. I scheduled an appt. to meet him personally. His agenda did not mesh with Ginna Laport's. He mentioned a transplant instead of Ginna's plan to keep me on maintenance meds. He should have consulted with her before she left. I do not want to return to Stanford.
Well prepared, good listener very bright.
Great experience.
The BMT Clinic is superlative.
Simply a good one.
Outstanding!
Very confident in Dr.Rezvani's knowledge, experience, and care. Always makes me feel taken care of.
Dr. Rezvani has been a pleasure to have as my treating physician.
I believe I am getting excellent care from Dr. Rezvani and Stanford in general.
Dr. Andrew Rezvani is an EXCELLENT listener and is SO KNOWLEDGEABLE about my case and the BMT process in general. He is an EXCELLENT doctor.
He is excellent. He really care for his patients.
Good.
View More »
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday – Friday, 8 a.m. – 5 p.m.
Fax: 650-320-9443
Monday – Friday, 8 a.m. – 5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referring Physicians.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or e-mail the Referral Center at ReferralCenter@stanfordhealthcare.org
- Send referrals online
- View referral status
- Access medical records